

# Using Patient Experience Data to Evaluate Medical Interventions

*Generating, understanding and using patient experience data within and alongside clinical trials.*

EDITOR: Dr Matthew Reaney

**This file contains only Chapter 7 of this book. For a full copy of the book please email [PCSBD@iqvia.com](mailto:PCSBD@iqvia.com)**

*Please cite this chapter as: Roborel De ClimensA, Casamayor M, Farrell M, Reaney M (2023). Generating patient experience data*

*(PED) in complex populations and programs; examples of pediatrics, central nervous system (CNS), cancer and rare disease. In Reaney M (ed.) Using Patient Experience Data to Evaluate Medical*

*Interventions. Generating, understanding and using patient*

*experience data within and alongside clinical trials. IQVIA. Pages 88-127.*



=IQVIA

# Table of Contents

- 1 Patient experience data (PED) in intervention development – what is it, why should you care, and how can this book help?

*Matt Reaney*

## Section 1: Generating patient experience data

- 2 Making use of existing data – approaches to identifying, appraising and interpreting secondary patient experience data (PED)

*Obinna Onwude, Betsy Williams*

- 3 Understanding patient experiences through qualitative research

*Robert Krupnick, Kimberly Kelly*

- 4 Collecting patient experience data (PED) with clinical outcome assessments (COAs)

*Oren Meyers, Isabelle Guillemin, Matt Reaney*

- 5 Patient preference research to understand patients' expectations and experiences

*Ana Maria Rodriguez-Leboeuf, Laurie Batchelder, Stephanie Philpott, Willings Botha*

- 6 The role of digital technology in generating and capturing patient experience data (PED)

*Pip Griffiths, Michael Posey*

- 7 Generating patient experience data (PED) in complex populations and programs; examples of pediatrics, central nervous system (CNS), cancer and rare disease

*Aude Roborel de Climens, Montse Casamayor, Meagan Farrell, Matt Reaney*

## Section 2: Understanding patient experience data

- 8 The importance of ensuring valid, reliable, responsive and interpretable patient experience data (PED)

*Christina Daskalopoulou, Konstantina Skaltsa*

und  
erst  
and  
and  
enh  
anc  
e  
pati  
ent  
exp  
erie  
nce  
dat  
a  
(PE  
D)

*Kate Hamilton-  
West, Rachel  
Bruce, Sandra  
van Os*



### **Section 3: Using patient experience data**

- 10** Integration of patient experience data (PED) into regulatory and payer decision-making Page 168  
*Joy Whitsett, Matt Reaney, Livia Lai*
- 11** Disseminating patient experience data (PED) to the medical and scientific community Page 188  
*Emily Ruzich, Cathy Yang, Twinkle Khera, Alise Nacson, Shweta Shah, Paul Williams*
- 12** Understanding how to communicate patient experience data (PED) to patients Page 202  
*France Ginchereau Sowell, Matt Reaney*

### **Section 4: Developing a patient experience data strategy**

- 13** A patient experience data (PED) roadmap for patient-focused intervention development, determination and evaluation Page 216  
*Juliet Davis, James Turnbull, Matt Reaney*

### **Author biographies**

Page 225



### CHAPTER 7

# Generating patient experience data (PED) in complex populations and programs; examples of pediatrics, central nervous system (CNS), cancer and rare disease

A ROBOREL DE CLIMENS, M CASAMAYOR, M FARRELL, M REANEY

## Key takeaways

- Pediatric populations
  - » Children should be able to engage in qualitative and quantitative patient experience data (PED) research from age 8.
  - » Between 5 and 8, validity of self-report is questionable and should be based on very simple, concrete, current, and sufficiently remarkable events.
  - » Asking concrete momentary assessments is recommended for young children and new digital technologies could help with this.
  - » When children are unable to self-report, observable facts should be evaluated by external persons, and proxy evaluation avoided.
- Populations with central nervous system (CNS) disorders
  - » Patients with CNS disorders experience a wide array of physical, cognitive and/or sensory limitations that can make it difficult for them to reflect and report on their experiences. Further, measurement of the patient experience in CNS disorders is often done through
- Cancer programs
  - » PED is increasingly important in the development of anti-cancer drugs, and in cancer care. However, generation of robust and informative PED is complicated by the increasing use of accelerated drug development programs and basket and super umbrella trials, high attrition rates, and a substantial amount of missing PED due to disease progression, treatment-related toxicity and death.
  - » Yet PED collection is possible and informative with appropriate planning.
- Rare disease programs
  - » Rare diseases are often complex, multisystemic and chronic. Most people with a rare disease will not be cured in their lifetimes, and thus identifying ways to improve quality of life (QoL) is important.



## Advice for researchers interested in collecting PED in complex populations and programs

- Pediatric populations
  - » The ability to collect valid PED with children will vary across age groups and developmental stages. Precautions and interactive approaches should be used to make children and adolescents comfortable and improve their engagement in PED research.
  - » The use of innovative, participatory and friendly digital health tools adapted to the pediatric population may improve compliance and collection of robust data.
- Populations with CNS disorders
  - » Researchers must evaluate whether patients with CNS disorders have sufficient capacity to provide accurate and reliable reports of their experiences.
- Cancer programs
  - » PED in cancer often comes from patient-reported outcome (PRO) instruments. Careful planning is essential for data analysis and interpretation. If accelerated approval is likely to be sought, standalone studies may be needed to support PRO interpretation, including the generation of psychometric evidence.
  - » Other forms of PED can be useful to supplement PRO data, including preference research.
- Rare disease programs
  - » PRO instruments should be used to collect information on QoL, where possible, from rare

**“You guys give up? Or are you thirsty for more?”**

— *Kevin McCallister in Home Alone (1990 film)*

Prior chapters in this book have outlined the approaches to generating reliable, valid, meaningful and interpretable patient experience data (PED) from qualitative and quantitative exploration. These approaches are, in most cases, tried and tested across drug development programs from various institutions and intervention developers/ sponsors. However, there are some populations in which the collection of PED is a bit more difficult. This includes collection of PED from people with symptoms that make reporting experiences difficult. This includes people with speech issues, physical limitations impacting on inability to complete surveys or clinical outcome assessments (COAs), or cognitive impairment. Two specific populations

in which the collection of PED needs special consideration are children and those with neurological or psychiatric

indications (summarized as “central nervous system (CNS) disorders”). This chapter will discuss the collection of PED in children and among people with CNS disorders.

In addition, prior chapters in this book have focused on collecting PED in a traditional model of drug development; that is a structured progression from Phase I, through Phase II and Phase III for registration. In some diseases, including oncology and rare disease, this may not be possible or necessary. This chapter will therefore also discuss the impact of novel development pathways on



the generation and use of PED in the context of oncology, and provide a short discussion on rare diseases for whom generation of PED have some additional nuances that are worth highlighting.

and used off-label in children.<sup>3,4</sup> However, children are not “little adults,” and interventions for children need

## Generating PED in pediatric populations

### A ROBOREL DE CLIMENS

**Chapter 3** of this book discuss the role of qualitative insights as the cornerstone of PED, explaining how discussions with patients are essential to understand perspectives of disease, preferences and priorities for treatment, and experiences of research studies. Subsequent chapters (**Chapters 4–6**) speak to the role of PED derived from structured outcome measures and surveys completed by the patient (patient-reported outcome (PRO) instruments; patient preference research) or delivered through technology worn by the patient.

These all inherently assume that reliable and valid PED can be generated from the patient population. This may not always be the case when trying to generate PED from children.

Children are defined – for the purpose of pediatric research – as those between the ages of 0 and 17. This is quite a large age range, with significant differences in motor, cognitive, linguistic, social and emotional development in infants, young children, adolescents, and young adults.<sup>1,2</sup> Acknowledging this broad age range, it is important to explore whether children can reliably report their experiences, and how to generate PED about those who cannot.

### HOW RELEVANT IS PED IN PEDIATRIC INTERVENTION DEVELOPMENT?

Some interventions are developed specifically for use in children, while others are developed for use in adults



specific considerations to ensure that they are meeting the priorities, needs and preferences of children and their caregivers. This information can be obtained through PED. For the collection of PED, researchers generally recommend direct reports from patients,<sup>5</sup> but this is not always easy in pediatric research and thus, children are not always asked to share their own experiences and insight to inform the development of interventions.<sup>6,7</sup> There are some initiatives, including the International Children's Advisory Network (iCAN), that are seeking to change this through generating a network of young persons' advisory groups (YPAGs) for intervention development. Research supports such initiatives, showing the potential for improved success in the trial process (including recruitment and retention) and subsequent health outcomes when involving children in design.<sup>8,9</sup> Researchers and families alike require training and education to be able to involve the pediatric patient in PED research in a sensitive manner.<sup>10</sup>

## **WHAT MAKES PED DIFFICULT TO GENERATE IN PEDIATRIC POPULATIONS?**

The generation of robust PED relies on good scientific research methods (as described in other chapters of this book) and a patient population willing and able to reflect on and share their insights, experiences, priorities, attitudes, knowledge and health-related behaviors. Some children – especially young children – may not be able to understand questions that researchers tend to ask to elicit PED, nor articulate their thoughts and feelings in a way that is easily interpretable to researchers. That does not, however, mean that robust PED cannot be collected in pediatric intervention development. Rather, care must be taken to maximize quality.<sup>9,11,12</sup>

## **HOW DO I COLLECT ROBUST PED IN PEDIATRIC RESEARCH?**

It is generally agreed that children's understanding of health-related concepts increases with age,<sup>2,13</sup> and while developmental evolution may not be the same in all

children,<sup>14</sup> age is a reasonable way in which to initially classify pediatric populations for PED research. The age at which children can provide reliable information in a qualitative interview (as described in **Chapter 3**) and

the age at which a child can reliably respond to a PRO instrument or preference survey (see **Chapters 4 and 5**) are two different issues.<sup>1</sup>

### **Qualitative PED research**

While it is impossible to collect health information

directly from infants,<sup>2</sup> children as young as 4 or 5 may be capable of providing some specific information

on concrete aspects of their health status (about events that are sufficiently remarkable).<sup>1</sup> But, it is not until age 8 that children are generally able to explain simple concepts like “pain” in their own words<sup>1,2</sup>; and even then only about their current or very recent experience.<sup>1,15</sup> At this stage (i.e., from age 8), it would

therefore be reasonable to engage children in simple

concept elicitation research; that is qualitative research to explore the patient experience of managing illness, disease or a condition (see **Chapter 3** for details). By the age of 12, most children can understand and answer questions about abstract concepts or hypothetical

events<sup>1</sup> and thus can be expected to answer the

same types of questions in qualitative research as adults. However, social and emotional aspects may be considered with caution in adolescents (age 12–17), as

they may not be willing to share.<sup>2</sup> This is particularly true when the discussion could cause embarrassment or shame, such as with sexual functioning.<sup>16</sup>

Special attention should be paid to standards for good practice in conducting interviews with older children (age 8–11) and adolescents (age 12–17). For example, the interviewer should learn the discussion guide well to adapt and improvise,<sup>17</sup> use warm-up exercises to

make children feel comfortable,<sup>18</sup> use age-appropriate language,<sup>1,14,16,19–21</sup> and ask questions in a neutral

manner with simple wording, avoiding clinical terms.<sup>16</sup> For adolescents (age 12–17), there are additional



considerations. For example, it is important to avoid “child-like” terms during the interview.<sup>16</sup> It may also be beneficial to have an interviewer of the same sex to encourage open and honest discussion, particularly about sensitive topics. The interviewer should emphasize at the beginning and during the interview that the adolescent is free to not answer any questions they are not comfortable with.

---

*It is not until age 8 that children are generally able to explain simple concepts like “pain” in their own words.*

As children have limited attention span<sup>14,19,22</sup> and

can easily become bored, it is also important to use interactive techniques to engage children in qualitative interviews.<sup>14,17,19,23</sup> The use of drawings, photographs, illustrations, props, and toys could be beneficial for children age 8–11, especially if they are shy.<sup>14,18,21</sup> Asking them first to draw a picture describing their condition or its impact, and then explain it, encourages children to share and help starting the discussion.<sup>1,14,15,18,21</sup> Similarly, photo-elicitation interviews have been shown to be particularly beneficial when working with children with poor written or verbal literacy.<sup>17,21,24–26</sup>

Social media can also be used to engage adolescents, provide a starting point for conversation, and facilitate an understanding of other people’s experiences.<sup>27</sup>

NHS (National Health Service) Digital’s Widening

Digital Participation Programme further recommends considering digital technologies as an enabler for

improving health services with adolescents.<sup>27</sup> Even with these techniques, the length of interviews should be

shorter for adolescents than it is for adults, and even shorter still for children age 8–11.<sup>1,23</sup> Several breaks

should also be made during an interview.<sup>1</sup>

以上内容仅为本文档的试下载部分，为可阅读页数的一半内容。如要下载或阅读全文，请访问：<https://d.book118.com/475240343224011214>